FDA Adverse Event Rating Scale Could Follow NCI Model, Consultant Says
Executive Summary
The National Cancer Institute Common Toxicity Criteria could be a model for a standardized adverse event severity scale, International Pharmaceutical Consultants President Herbert Swarz, MD, suggested during a May 22 FDA hearing on risk management